Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

INITIATOR PHARMA: INTERIM REPORT JANUARY- JUNE 2021

Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016. Second Quarter (2021-04-01 – 2021-06-30) · Net revenues were TDKK 0 (0) · EBIT was TDKK -4,944 (-3,013) · Earnings per share was DKK –0.14 (-0.13) First Six Months of the Year (2021-01-01 – 2021-06-30) · Net revenues were TDKK 0 (0) · EBIT was TDKK -6,736 (-5,405) · Earnings per share was DKK –0.19 (-0.23) · Cash and bank: TDKK 31,099 (8,189) · Solidity:

ORGANOCLICK AB (PUBL) PUBLISH INTERIM REPORT FOR Q2 2021

"During the second quarter, we recorded our highest quarterly sales ever of a total of SEK 39.8 (36.1) million,which resulted in growth of 10.4 (10.3) %. We also signed agreements with the new customers Stadium, Hööksand XXL Norway for OrganoTex where we continue our expansion. At the end of the quarter, we also deliveredour first bulk delivery of our biobased binders to Duni, which is now preparing its launch of fossil-free napkins."Translation from CEO Mårten Hellbergs comments to the Interim Report.   Q2, 1 April - 30 June 2021 The Group compared with 2020 » Net revenue

Continued Growth and Strengtened Gross Margin Led to Improved Operating Income during the Second Quarter

PowerCell Sweden AB grew its sales by 28 percent during the second quarter 2021, from MSEK 22.2 to MSEK 28.2. Operating income improved to MSEK -21.7 (-28.3) driven by increased sales and strengthened gross margin.In terms of sales, the second quarter 2021 was the strongest second quarter in the company’s history. This was the third quarter in a row with record sales in comparison with corresponding quarters previous years. “Growth was driven by increased demand in all segments while also sales to Robert Bosch remained high. Underlying demand was stronger than what can be seen in the

SRV Group Plc’s financial information in 2022

SRV GROUP PLC     STOCK EXCHANGE RELEASE     20 AUGUST 2021     9.30 EET  SRV Group Plc’s financial information in 2022 SRV Group Plc will publish the following financial information in 2022: · Financial Statement Release 2021 will be published on Thursday, 3 February 2022 at 8.30 am. · Annual Report 2021 (including the Financial Statements and the Report of the Board of Directors) will be published on Wednesday, 2 March 2022. · Interim Report for January-March 2022 will be published on Thursday, 28 April 2022 at 8.30 am. · Half-year Report for January-June 2022 will be

Heliospectra (publ) Half Year Report January-June 2021

(Gothenburg, Sweden August 20th, 2021)– Heliospectra AB (publ (Nasdaq First North Growth Market: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents its’ Half Year Report for January-June 2021.Full report is enclosed to this press release and is also uploaded at https://www.heliospectra.com/investor-relations/investor-relations. SUMMARY OF REPORT: Sales And Financial Performance, January–June Order intake during the period April - June amounted to SEK -61,492 thousand. This figure includes the order

SynAct Pharma to present new data on AP1189 for the treatment of rheumatoid arthritis at ACR Convergence 2021

SynAct Pharma AB (“SynAct”) today announced that an abstract entitled ”AP1189: A Novel Oral Biased Melanocortin Agonist with Anti-inflammatory and Pro-resolving Effect for the Treatment of Rheumatoid Arthritis” has been selected for presentation at the ACR Convergence 2021 conference on November 9. AP1189 is a novel oral available compound with anti-inflammatory and pro-resolving effect with the potential to treat active rheumatoid arthritis (RA).SynAct Pharma will present the compound’s topline pharmacology and efficacy data at the event. The compound is currently being tested in a double-

Fossil free energy from Vattenfall enables reduced emissions in Orthex´s production

Vattenfall delivers 100 percent fossil free hydro power to Orthex´s factories in Sweden and Finland. This is an important part in Orthex´s ongoing sustainability work and goal to be carbon neutral in production by 2030.Last year, Vattenfall and Orthex Corporation, a leading Nordic producer of household products, signed an electricity supply agreement of 100 percent electricity from hydro power labelled EPD (Environmental Product Declaration) to the factory in Lohja, Finland. As of 2021 Vattenfall also delivers 100 percent electricity from hydro power labelled EPD to Orthex´s factories in

Fossil free energy from Vattenfall enables reduced emissions in Orthex’s production

Orthex Corporation, Press release, August 20, 2021 at 9.15 a.m. EEST Vattenfall delivers 100 percent fossil free hydro power to Orthex’s factories in Sweden and Finland. This is an important part in Orthex´s ongoing sustainability work and goal to be carbon neutral in production by 2030.Last year, Vattenfall and Orthex Corporation, a leading Nordic producer of household products, signed an electricity supply agreement of 100 percent electricity from hydro power labelled EPD (Environmental Product Declaration) to the factory in Lohja, Finland. As of 2021 Vattenfall also delivers 100

poLight ASA – purchase order received for mass production preparation for a surgical device

Horten, 20 August 2021 - poLight ASA (OSE: PLT) today announced that the company has received a purchase order for TLens, including a custom assembly service, in preparation for mass production of an ultra-compact surgical device under development by a medical customer worth NOK 2.300.000. “This purchase order gives us an exciting opportunity to expand into the medical market segment for the first time. Our customer’s surgical device that uses our TLens AF enabled camera is still under development and changes may happen, but as of now we are designed in and our customer’s initial

Update on Ultomiris Phase III ALS trial

20 August 2021 07:05 BST Update on CHAMPION-ALS Phase III trial of Ultomiris in amyotrophic lateral sclerosis     Alexion is discontinuing CHAMPION-ALS, the global Phase III clinical trial of Ultomiris (ravulizumab) in adults with amyotrophic lateral sclerosis (ALS).   This decision is based on the recommendation of the Independent Data Monitoring Committee (IDMC), following their review of data from a pre-specified interim analysis. The IDMC recommended that the trial be discontinued due to lack of efficacy. No new safety findings were observed and the data were

ALL-TIME HIGH REVENUE AND PROFITABILITY

SECOND QUARTER, APRIL – JUNE 2021 · Net sales increased by 21.6%, or 24.0% FX adjusted, to MSEK 78.5 (64.6) · Gross profit increased by 34.0%, or 37.0% FX adjusted, to MSEK 61.3 (45.7) · EBIT increased to MSEK 11.7 (4.7) · Earnings after tax was MSEK 10.7 (2.8) · Earnings per share was, basic SEK 1.35 (0.35), diluted SEK 1.35 (0.35)  FIRST HALF YEAR, JANUARY – JUNE 2021 · Net sales increased by 12.0%, or 14.1% FX adjusted, to MSEK 150.1 (134.0) · Gross profit increased by 17.5%, or 20.1% FX adjusted, to MSEK 115.1 (98.0) · EBIT increased to 18.2 MSEK (4.4)

Fuud secures central listing for iQ Fuel at S-gruppen and strengthens organisation in Finland

STOCKHOLM, 20 aug, 2021 08.00 CEST The fast-growing brand iQ Fuel, which was acquired by Fuud in the spring of 2021, will be centrally listed at the market-leading Finnish food chain S-gruppen, which has approximately 1,100 stores in the country. At the same time, Fuud is strengthening its organization in Finland by hiring Casimir Reincke as Country Manager, who will begin building up Fuud's Finnish organization. Three salespeople are recruited immediately to handle the introduction of iQ Fuel together with other brands in Fuud's portfolio. Casimir has previously successfully built up the

American Shipping Company ASA - Second quarter 2021 results

Lysaker, 20 August 2021, American Shipping Company ASA (“AMSC” or the “Company”) announces results for the second quarter ending 30 June 2021. HIGHLIGHTS · Stable Q2 financial performance with bareboat revenue of USD 21.9 million, normalized EBITDA of USD 21.4 million and adjusted net profit of USD 4.0 million · Declared Q2 dividend of USD 0.10 per share, supported by the Company’s free cash flow · Backlog of secured bareboat revenue of USD 192 million with average weighted tenor of 2.2 years · The Company executed a USD 20 million tap issue under the senior unsecured bond

AZD7442 prophylaxis trial met primary endpoint

20 August 2021 07:00 BST AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 77% reduced risk of developing symptomatic COVID-19  First long-acting antibody combination to prevent COVID-19 Positive high-level results from the PROVENT Phase III pre-exposure prophylaxis trial showed AstraZeneca's AZD7442 achieved a statistically significant reduction in the incidence of symptomatic COVID-19, the trial's primary endpoint.   AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by

Eurobattery Minerals AB hereby publishes its Interim Report January – June 2021

Second quarter 2021 (same period previous year) · Net sales amounted to SEK 0 thousand (SEK 0 thousand). · Operating income after depreciation/amortisation and financial items totalled SEK –4,121 thousand (SEK –2,934 thousand). · Earnings per share after depreciation/amortisation and financial items amounted to SEK –0.26 (SEK –0.53). · Cash flow from operating activities was SEK –3,150 thousand (SEK –1,124 thousand). First half year 2021 (same period previous year) · Net sales amounted to SEK 0 thousand (SEK 0 thousand). · Operating income after depreciation/

Half-Year Financial Report, January – June 2021

Half-Year Financial Report 2021   Second quarter highlights ·Revenue increased by 52% to MEUR 23.2 (15.2) · EBITDA increased to MEUR 4.3 (1.4), corresponding to a 19% (9%) EBITDA margin · EBIT increased to MEUR 2.2 (-0.5), corresponding to a 10% (-4%) EBIT margin · Operational cash flow increased to MEUR 1.3 (0.4). As planned, the strategic actions to mitigate possible global supply chain disruptions caused by global component shortages continued to have a negative impact to the Operational Cash Flow  Significant events during the quarter ·iLOQ Rapide –

Interim report: Production start approaching as planned

Azelio strengthened its commercial organisation in the second quarter by establishing sales organisations in Australia, South Africa and the Middle East. Moreover, the company was selected for Accelerator programmes in India and Indonesia with the aim of introducing Azelio’s technology in collaboration with the Swedish Energy Agency and Business Sweden. Preparations for the start of production at the end of September are progressing as planned and include securing the supply chain as well as the design and fine tuning of numerous new processes. In addition, a memorandum of understanding (

Hemnet Group Interim report Q2 2021

Strong growth in net sales and adjusted EBITDA Summary for the period April-June 2021  · Net sales increased 47.4 percent to SEK 212.5m (144.2) · Adjusted EBITDA increased 103.9 percent to SEK 110.9m (54.4) · Operating profit increased 108.3 percent to SEK 62.9m (30.2) · Strong year-on-year listings growth that increased 18.8 percent compared to the previous year · The first full quarter with both the segmented price model on all seller products and the new compensation model for real estate agent offices, leads to significant operational leverage  Summary for the

Cessatech reports first patient dosed in pharmacokinetic trial in children of lead product candidate

Clinical trial 0206 will investigate the pharmacokinetics  in children aged 1-17 undergoing elective surgical procedures. Primary aim of this trial is to obtain pharmacokinetic data from this age group and to demonstrate that CT001 nasal spray is feasible as premedication in children undergoing anaesthesia.Cessatech A/S announces that the pharmacokinetic trial (0206) in children has been initiated according to plan and that the first patient has been dosed. The trial is designed as a non-randomized, open-label study in 25 children aged 1-17 years needing premedication for placement of a

Humana reports second quarter and half-year 2021 results

A stable second quarterSecond quarter, April–June 2021 · Operating revenue was SEK 2,058m (1,980), an increase of 4.0 percent. Organic growth was 3.4 percent. · Operating profit amounted to SEK 107m (100), an increase of 6.6 percent. Capital gain on sale of properties of SEK 17m is included in the comparison period. Adjusted operating profit was SEK 107m (83), an increase of 28.4 percent. · Net profit after tax for the period amounted to SEK 57m (50). · Basic and diluted earnings per share for the period amounted to SEK 1.18 (0.94). · Operating cash flow amounted to SEK

Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2021 Results Presentation Webcast

Oslo, Norway, 20 August 2021 Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the second quarter and first half 2021 on Friday, 27 August 2021. A presentation by Nordic Nanovector’s senior management team will be webcast live the same day beginning at 8:30am CEST. The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event. The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports

SaltX Technology Holding AB Interim report 2 2021

FINANCIAL EVENTS Second quarter · Net sales amounted to MSEK 0.1 (0.0) · Operating profit/loss (EBIT) totaled MSEK -7.9 (-8.2) · Cash flow from operating activities amounted to MSEK -10.3 (-10.2) · Earnings per share before and after dilution amounted to SEK -0.08 (-0.09) Year to date January - June · Net sales amounted to MSEK 0.1 (0.1) · Operating profit/loss (EBIT) totaled MSEK -16.0 (-17.3) · Cash flow from operating activities amounted to MSEK -18.1 (-19.2) · Earnings per share before and after dilution amounted to SEK -0.19 (-0.21)  SIGNIFICANT

There are no items matching the current filter
There are no more items matching the current filter
Back to top